A new nanoparticle hydrogel developed by orthopedic researchers shows promise for strengthening bones weakened by osteoporosis. In a recent study published in the journal Bone, experts suggest that this innovative solution could help patients prevent potentially fatal osteoporotic fractures.
Osteoporosis is an incurable condition that affects approximately 50 percent of women and 25 percent of men over the age of 50. Fragile and brittle bones often lead to osteoporotic fractures, which can result in significant long-term complications, including mortality. While current medications aim to reduce bone resorption or promote new bone formation, they may take up to a year to show noticeable effects.
Dominque Pioletti, head of the Laboratory of Biomechanical Orthopedics at Switzerland’s Ecole Polytechnique Fédérale de Lausanne (EPFL) and study coauthor, highlighted the alarming statistics related to osteoporotic fractures, emphasizing the need for effective preventive measures.
The innovative approach developed by Pioletti’s team, in partnership with EPFL startup Flowbone, targets potential fracture sites directly. Unlike traditional pastes that harden into cement-like material, this new treatment utilizes a hydrogel composed of hyaluronic acid and hydroxyapatite nanoparticles, mimicking the natural minerals found in bones.
In animal trials, the hydrogel injected into rats with osteoporosis resulted in a significant increase in local bone density within a few weeks. When combined with the anti-catabolic drug Zoledronate, the bone density at the injection site saw a substantial improvement in a short period.
While the hydrogel injections are not a cure, they can complement existing therapies to accelerate relief and recovery for patients. Pioletti’s team and Flowbone aim to conduct clinical trials in humans after obtaining regulatory approval, with the ultimate goal of developing therapies to prevent osteoporotic fractures.
Source: Popular Science
